Post

Betta to commercialise C4 Therapeutics’ CFT8919 in greater China

C4 Therapeutics has entered into an exclusive licensing agreement with Betta Pharmaceuticals to develop and commercialise CFT8919 across the greater …

XtalPi announces $250m AI drug discovery collaboration with Eli Lilly

XtalPi has made a partnership deal with US-based Eli Lilly to leverage artificial intelligence (AI) for drug discovery. XtalPi will receive …

FDA accepts Bristol Myers Squibb’s repotrectinib NDA for review

The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s new drug application (NDA) for repotrectinib for priority …

University of Sydney will use AI to boost cancer drug research

The University of Sydney and Australian company Pharos Therapeutics have reached an agreement to leverage artificial intelligence (AI) to progress …

Early signals suggest oral SERD’s potential for more breast cancer patients

The Menarini Group today has announced exploratory results from its EMERALD clinical study that suggest its recently approved oral selective …